Inflammation Drives Sickle Cell Disease Pathophysiology

Sickle cell disease (SCD) is an inherited haemoglobinopathy characterised by the polymerisation of deoxygenated haemoglobin S, leading to red blood cell sickling. This process results in chronic haemolytic anaemia and recurrent vaso-occlusive crises (VOCs). However, the pathophysiology of SCD is complex and involves a significant inflammatory component. Chronic inflammation is a hallmark of SCD, contributing to both acute complications like VOCs and long-term organ damage.¹

The inflammatory cascade in SCD is initiated by multiple factors. Haemolysis releases cell-free haemoglobin and heme, which are potent pro-oxidants and activators of innate immune pathways.² Endothelial dysfunction, driven by nitric oxide scavenging and oxidative stress, promotes the adhesion of sickled red blood cells, leukocytes, and platelets to the vascular endothelium. This adhesion is mediated by increased expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin.³

Leukocytes, particularly neutrophils, play a central role in the inflammatory response in SCD. Patients with SCD often exhibit chronic leukocytosis, and neutrophil activation is heightened during VOCs. Activated neutrophils release pro-inflammatory mediators, including myeloperoxidase and neutrophil extracellular traps (NETs), which contribute to vascular occlusion and tissue injury.⁴ Platelet activation and aggregation are also prominent features, further contributing to the pro-thrombotic and pro-inflammatory environment.⁵

SCD affects millions globally, with a higher prevalence in sub-Saharan Africa, India, and the Middle East. The clinical presentation varies widely among individuals, ranging from mild symptoms to severe, life-threatening complications. The chronic nature of the disease and its systemic impact underscore the need for comprehensive management strategies that address not only the primary sickling phenomenon but also the pervasive inflammatory state. Understanding the specific mechanisms by which inflammation contributes to disease progression is crucial for developing targeted therapies.

Inflammatory Culprits and Consequences

Multiple pro-inflammatory cytokines are consistently elevated in patients with SCD, even during steady state. These include interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α).⁶ These cytokines perpetuate the inflammatory cycle by stimulating endothelial cells, leukocytes, and other cell types to produce more inflammatory mediators and adhesion molecules. For instance, IL-6 is a key driver of the acute phase response, leading to elevated C-reactive protein (CRP) levels, which are often used as a marker of inflammation in SCD.⁷

The chronic inflammatory state has significant clinical consequences. It contributes to the frequency and severity of VOCs by promoting cell adhesion and microvascular occlusion.⁸ Furthermore, sustained inflammation is implicated in the development of chronic organ damage, including pulmonary hypertension, nephropathy, cerebrovascular disease, and avascular necrosis.⁹ For example, chronic inflammation in the lungs can lead to pulmonary fibrosis and contribute to acute chest syndrome, a severe complication of SCD.¹⁰ In the kidneys, chronic inflammation and oxidative stress contribute to glomerulosclerosis and progressive renal dysfunction.¹¹

Targeting specific inflammatory pathways represents a promising therapeutic strategy. Anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (NSAIDs), are used for pain management during VOCs, but their systemic effects and potential for adverse events limit long-term use.¹² Emerging therapies are exploring more specific anti-inflammatory targets. For example, inhibition of P-selectin, an adhesion molecule involved in leukocyte and sickled red blood cell adhesion, has shown efficacy in reducing VOCs.¹³ Other approaches include targeting specific cytokines or pathways involved in NET formation.¹⁴

While hydroxyurea remains the cornerstone of SCD management, primarily by increasing fetal haemoglobin (HbF) and reducing sickling, its anti-inflammatory effects are also recognised. Hydroxyurea can reduce leukocyte counts and decrease the expression of adhesion molecules, thereby mitigating some aspects of the inflammatory response.¹⁵ However, for many patients, hydroxyurea alone is insufficient to control the chronic inflammatory burden and prevent complications. Further research into the precise mechanisms of inflammation in SCD and the development of novel anti-inflammatory agents is ongoing, with several compounds in various stages of clinical development.¹⁶ Limitations in current anti-inflammatory approaches include the broad-spectrum nature of some agents, leading to off-target effects, and the challenge of achieving sustained anti-inflammatory action without compromising host defense mechanisms. Future research aims to develop highly specific inhibitors that can modulate key inflammatory pathways while minimizing adverse effects.